Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 4/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100241 | 0.92 | JAK2 (0.61) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100242 | 0.89 | JAK2 (0.60) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL12423671 | 0.87 | JAK2 (0.45) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL12423747 | 0.87 | JAK2 (0.46) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL12423656 | 0.86 | JAK2 (0.51) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100344 | 0.85 | ABL1 (0.49) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100238 | 0.84 | JAK2 (0.50) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100374 | 0.84 | KLKB1 (0.46) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100235 | 0.83 | ABL1 (0.67) | JAK2JAK3ABL1BCRSYK | |
| SCHEMBL14100248 | 0.83 | ABL1 (0.52) | JAK2JAK3ABL1BCRIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | JAK2 1688/4885JAK3 1221/4885ABL1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.